:
The method of cellular reprogramming using small molecules involves manipulation of somatic cells to generate desired cell types under chemically limited conditions, thus avoiding the ethical controversy of embryonic stem cells
and the potential hazards of gene manipulation. The combinations of small molecules and their effects on mouse and human somatic cells are similar. Several small molecules, including CHIR99021, 616452, A83-01, SB431542, forskolin,
tranylcypromine and valproic acid [VPA], have been frequently used in reprogramming of mouse and human somatic
cells. This indicated that the reprogramming approaches related to these compounds were essential. These approaches
were mainly divided into four classes: epigenetic modification, signal modulation, metabolic modulation and senescent
suppression. The structures and functions of small molecules involved in these reprogramming approaches have been
studied extensively. Molecular docking gave insights into the mechanisms and structural specificities of various small
molecules in the epigenetic modification. The binding modes of RG108, Bix01294, tranylcypromine and VPA with their
corresponding proteins clearly illustrated the interactions between these compounds and the active sites of the proteins.
Glycogen synthase kinase 3β [CHIR99021], transforming growth factor β [616452, A83-01 and SB431542] and protein
kinase A [forskolin] signaling pathway play important roles in signal modulation during reprogramming, however, the
mechanisms and structural specificities of these inhibitors are still unknown. Further, the number of small molecules in the
approaches of metabolic modulation and senescent suppression were too few to compare. This review aims to serve as a
reference for reprogramming through small molecules and benefit future regenerative medicine and clinical drug discovery.